For Research Use Only. Cagrilintide is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.
Recent Peer-Reviewed Research Context
Beyond supplier evaluation, investigators sourcing cagrilintide should anchor protocol design in the primary clinical literature that defined the molecule. The pivotal phase 2 dose-finding study, Lau and colleagues in The Lancet (2021), reported placebo-subtracted weight reductions reaching 10.8 percent at the 4.5 mg weekly dose over 26 weeks, with a clear linear dose-response and a tolerability profile dominated by transient gastrointestinal events. The trial enrolled at 57 sites across 10 countries and remains the reference dose-response anchor for any preclinical work intended to translate to the human exposure range.
The cagrilintide plus semaglutide combination (CagriSema) was characterized in the Frias and colleagues phase 2 trial in The Lancet (2023), which demonstrated additive HbA1c and body-weight reductions in type 2 diabetes versus semaglutide monotherapy. For rodent CagriSema studies, this paper sets the in vivo benchmark that combination-treated arms should reproduce qualitatively: greater food-intake suppression than either monotherapy, durable weight separation through the dosing window, and glucose-control improvements that are not explained by weight loss alone. Mechanistic work on amylin-receptor signaling continues to appear in Cell Metabolism and the Frontiers in Endocrinology amylin coverage, both useful entry points for designing receptor-level assays alongside whole-animal endpoints.
For investigators selecting between amylin-class tools, pramlintide remains the short-acting reference and cagrilintide the long-acting comparator. The two together form a useful titration series for separating tonic from pulsatile amylin-receptor engagement, and the dose-response data from Lau 2021 and Frias 2023 give the translational anchors needed to interpret rodent body-composition and indirect-calorimetry endpoints.
What Research Grade Cagrilintide Supply Requires
Cagrilintide is a long acting amylin analog with lipidation chemistry that extends the plasma half life through albumin binding. The analytical characterization therefore has to confirm both the correct peptide sequence and the correct lipid modification, similar to the requirements for GLP-1 SM but with peptide specific features that distinguish cagrilintide from other lipidated research peptides.
The peptide portion of cagrilintide derives from native amylin with modifications that improve solubility and stability. The sequence has specific residue compositions that support amylin receptor agonist activity while resisting the physicochemical aggregation that native amylin is prone to. The analytical verification has to confirm these modifications along with the lipidation.
Midwest Peptide supplies Cagrilintide 5mg with third party certificates of analysis that address the full analytical package expected for a modified lipidated peptide.
Sourcing Criteria for Research Grade Cagrilintide
Third party certificate of analysis. Independent analytical verification with documented peptide sequence, lipidation confirmation, and purity values per lot.
Purity specification. Research grade cagrilintide is supplied at a minimum of ninety five percent HPLC purity.
Mass confirmation of the modified peptide. The observed mass by mass spectrometry should match the theoretical mass of the fully modified compound.
Lot traceability. Lot numbers on the vial should match the certificate of analysis for full reproducibility.
Research appropriate formulation. Cagrilintide is supplied as a lyophilized powder in research appropriate vial formats. The standard unit is five milligrams per vial.
Research use only compliance. The cagrilintide research cluster covers the preclinical research applications including the amylin receptor biology, satiety research, gastric emptying research, cagrisema combination research, weight maintenance research, and comparative research with pramlintide.
Shipping and logistics. Domestic shipping from Mission, Kansas through ShipStation and UPS.
Payment flexibility. Zelle (five percent discount), CashApp, Venmo, Azeban Pay, and Coinbase Commerce.
Research support. Direct support through 636-734-2390 and the contact page on the Midwest Peptide website.
Red Flags When Evaluating Suppliers
No lipidation confirmation. The lipid modification must be confirmed analytically.
Purity below research grade or unspecified. Ninety five percent HPLC purity minimum with lot specific values.
Internal certificate only. Third party verification is the research grade standard.
Health claims or implied human use. Suppliers operating outside the research use only framework are disqualified.
Unclear amylin analog identification. Cagrilintide is distinct from pramlintide and from native amylin. A supplier that does not clearly identify the compound is not positioned for rigorous research supply.
Research Applications Summary
The cagrilintide research cluster covers the complete landscape. The short summary is that cagrilintide is studied in rodent research models for effects on satiety, gastric emptying, body composition, glucose regulation, and combined metabolic outcomes with GLP-1 receptor agonists.
Comparative research with pramlintide, discussed in the comparison article, provides context for the distinct pharmacokinetic profile of the long acting analog versus the short acting reference compound.
Combined research with semaglutide, as the cagrisema combination discussed in the cagrisema article, is supported by the parallel catalog offerings at Midwest Peptide. The combination research represents one of the more interesting active areas of incretin plus amylin research.